Inven2, the tech transfer office for the University of Oslo and Oslo University Hospital, is bringing in Hans Vassgård Eid to increase its focus on investments.
Eid will work in the newly established Finance and Investments department, which has been set up to further develop Inven2’s role as an active early-stage investor.
He boasts more than three decades of experience working in finance, investments, and strategy. He was most recently chief financial officer of cancer treatment developer Zelluna from March 2025 to January 2026.
Before this, he served as chief financial officer of immunotherapies developer Ultimovacs for ten years, and concurrently as interim CEO from December 2024 to March 2025.
“We are delighted to have Hans Vassgård Eid join our team. His experience will be a significant asset in developing Finance and Investments as a clear and strategic focus area at Inven2.”
Anders Kapstad, vice president, finance and investment
Inven2’s move to become a more active early-stage investor follows the tech transfer organisation’s LP commitment that helped launch Aleap Ventures in September, as The Next Leap reported at the time.
